HLS Therapeutics Inc. (HLS) Q3 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Hls Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.239 Good morning and welcome to Q3 2025 Financial Results Conference Call for 00:00:05.239 -- 00:00:10.567 HLS Terfutics. At this point, I would like to turn the call over to David Mason, Investor 00:00:10.567 -- 00:00:14.890 Relations, for the introductory remarks. Please go ahead. 00:00:15.013 -- 00:00:19.159 Thank you. Good morning, everyone, and thank you for joining us today. 00:00:19.159 -- 00:00:24.467 With me on the call is Craig Millian, Chief Executive Officer, John Hanna, 00:00:24.467 -- 00:00:29.377 Chief Financial Officer, and Brian Walsh, Chief Commercial Officer. 00:00:29.377 -- 00:00:34.102 Earlier this morning, we issued a news release announcing our financial results for the 00:00:34.102 -- 00:00:37.746 three and nine months ended September 30, 2025. 00:00:37.746 -- 00:00:42.952 This news release, along with our MD&A and financial statements, 00:00:42.952 -- 00:00:47.935 is available on HLS's website and on CDAR+. 00:00:48.178 -- 00:00:53.584 Please note that slides accompanying today's call can be viewed by the webcast, 00:00:53.584 -- 00:00:58.391 a link to which is available in our earnings press release and at our website on the 00:00:58.391 -- 00:01:01.872 events and presentations page. 00:01:02.014 -- 00:01:06.418 Certain matters discussed in today's conference call or answers that may be given to 00:01:06.418 -- 00:01:10.222 questions could constitute forward-looking statements. 00:01:10.222 -- 00:01:14.526 Actual results could differ materially from those anticipated. 00:01:14.526 -- 00:01:19.071 Risk factors that could affect results are detailed in the company's annual information 00:01:19.071 -- 00:01:23.053 form, which has been filed on CDAR+. 00:01:23.495 -- 00:01:26.954 During the call, we will refer to ...